{
  "patent_number": "US 20220096616",
  "country": "US",
  "title": "Using Two Specific RNAs to Teach the Body to Fight Lung Cancer",
  "original_title": "Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)",
  "summary": "This patent describes an active composition containing two specific messenger RNAs, NY-ESO-1 and MAGE-A3, designed to stimulate an immune response in a mammal to treat lung cancer, especially non-small cell lung cancers.",
  "what_it_does": "The patent claims an \"immunostimulatory composition\" (Claim 25) that includes two specific RNA molecules. The first RNA carries instructions for making a protein called NY-ESO-1, and the second RNA carries instructions for making MAGE-A3. These proteins are known as antigens because they can trigger an immune response. The idea is that when these RNAs are introduced into the body, cells will produce these specific tumor proteins, teaching the immune system to recognize and attack cancer cells that also have these proteins. The RNAs can also have special parts like 5' and 3' UTR sequences, a Poly-A sequence, and a 5' Cap (Claims 26-29) to make them more stable and effective. They can also be combined with \"cationic compounds\" like lipids or peptides (Claims 30-32) to help them get into cells. For example, a doctor might administer this composition to a patient with non-small cell lung cancer to help their body fight the disease by stimulating an anti-tumor immune response (Claim 43).",
  "what_it_does_not_cover": [
    "Compositions that do not include both a first RNA encoding NY-ESO-1 and a second RNA encoding MAGE-A3 as core components (Claim 25).",
    "Immunotherapies that rely on DNA or protein-based vaccines instead of RNA molecules (Claims consistently specify \"RNA\" and \"mRNA\").",
    "Compositions where the coding regions of the NY-ESO-1 or MAGE-A3 RNAs are not at least 85% identical to the specified sequences (SEQ ID NO: 21 and SEQ ID NO: 17, respectively), particularly if G/C content is increased (Claims 34, 38).",
    "Methods of treating cancer that do not involve stimulating an anti-tumor immune response in the subject (Claim 43).",
    "Compositions using entirely different tumor antigens as the primary active ingredients, without including NY-ESO-1 and MAGE-A3."
  ],
  "filed": "2021-07-19",
  "granted": null,
  "expires": "2041-07-19",
  "status": "active",
  "holder": "Curevac AG",
  "holder_url": "https://patentbrief.org/company/curevac-ag",
  "inventors": [
    {
      "name": "Thomas Lander",
      "url": "https://patentbrief.org/inventor/thomas-lander"
    },
    {
      "name": "Ingmar Hoerr",
      "url": "https://patentbrief.org/inventor/ingmar-hoerr"
    },
    {
      "name": "Marijke Barner",
      "url": "https://patentbrief.org/inventor/marijke-barner"
    },
    {
      "name": "Jochen Probst",
      "url": "https://patentbrief.org/inventor/jochen-probst"
    }
  ],
  "times_cited": 7,
  "tags": [
    "biotech",
    "pharmaceutical",
    "gene_editing",
    "oncology"
  ],
  "abstract": "The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.",
  "url": "https://patentbrief.org/patent/us/20220096616/composition-for-treating-lung-cancer-particularly-of-non-small-lung-cancers-nscl",
  "markdown_url": "https://patentbrief.org/patent/us/20220096616/composition-for-treating-lung-cancer-particularly-of-non-small-lung-cancers-nscl/md",
  "google_patents_url": "https://patents.google.com/patent/US20220096616",
  "relatedPatents": [
    {
      "patentNumber": "20160168227",
      "countryCode": "US",
      "title": "How an mRNA Vaccine for Lung Cancer Teaches the Immune System to Fight",
      "url": "https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer"
    },
    {
      "patentNumber": "12048738",
      "countryCode": "US",
      "title": "Using mRNA to Teach the Body to Fight Prostate Cancer",
      "url": "https://patentbrief.org/patent/us/12048738/composition-for-treating-prostate-cancer-pca"
    },
    {
      "patentNumber": "20160166668",
      "countryCode": "US",
      "title": "How an mRNA Vaccine Targets Prostate Cancer with Six Antigens",
      "url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer"
    },
    {
      "patentNumber": "11407807",
      "countryCode": "US",
      "title": "Using Specific Immune Cells to Fight Cancers Like Lung and Breast Cancer",
      "url": "https://patentbrief.org/patent/us/11407807/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-tu"
    },
    {
      "patentNumber": "10314897",
      "countryCode": "US",
      "title": "How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer",
      "url": "https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca"
    }
  ]
}